I would say that there are two big themes in that space. One is trying to understand how to give more or better drugs to those who are at particularly high-risk. So the cooperative groups are attending to those questions. They’re going to require very large studies to ask and answer those questions. So for patient- who receive the KEYNOTE-522 regimen, but have residual disease at the time of surgery, those patients are at extremely high risk of developing a distant recurrence...
I would say that there are two big themes in that space. One is trying to understand how to give more or better drugs to those who are at particularly high-risk. So the cooperative groups are attending to those questions. They’re going to require very large studies to ask and answer those questions. So for patient- who receive the KEYNOTE-522 regimen, but have residual disease at the time of surgery, those patients are at extremely high risk of developing a distant recurrence.
And so the cooperative groups are going to look at combining an antibody-drug conjugate together with pembrolizumab versus the standard of care pembrolizumab. So escalation of therapy for those who are at highest risk. And then on the flip side is de-escalation of therapy for those who are going to have great outcomes and maybe require less therapy. So those are the two big themes for study in that space.